AIM ImmunoTech Inc
AIM1.155USD
-0.055-4.55%
Market hours （ET）Quotes delayed by 15 min
3.20MMarket Cap
LossP/E TTM
More Details of AIM ImmunoTech Inc Company
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Inc Info
Ticker SymbolAIM
Company nameAIM ImmunoTech Inc
IPO dateJul 12, 1996
CEOEquels (Thomas K)
Number of employees21
Security typeOrdinary Share
Fiscal year-endJul 12
Address2117 Sw Highway 484
CityOCALA
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code32801
Phone13524487797
Websitehttps://aimimmuno.com/
Ticker SymbolAIM
IPO dateJul 12, 1996
CEOEquels (Thomas K)
Company Executives of AIM ImmunoTech Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.91K
-15.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-3.00%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-1.00%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
-1.00%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.91K
-15.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-3.00%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-1.00%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
-1.00%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.31%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
Other
94.19%
Shareholders
Shareholders
Proportion
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.31%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
Other
94.19%
Shareholder Types
Shareholders
Proportion
Individual Investor
3.86%
Investment Advisor
2.18%
Investment Advisor/Hedge Fund
1.58%
Other
92.38%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
56
107.25K
2.64%
--
2025Q3
59
107.25K
2.79%
+95.13K
2025Q2
58
12.12K
12.55%
-36.20K
2025Q1
67
48.31K
13.00%
-45.65K
2024Q4
64
46.48K
14.87%
-43.65K
2024Q3
61
90.13K
15.18%
+5.69K
2024Q2
61
84.44K
8.12%
+43.50K
2024Q1
64
40.95K
9.51%
-6.49K
2023Q4
65
41.55K
9.71%
-1.72K
2023Q3
69
43.37K
10.32%
-1.62K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
DRW Securities, LLC
43.29K
1.52%
+43.29K
--
Sep 30, 2025
Equels (Thomas K)
38.87K
1.36%
-15.00
-0.04%
Oct 24, 2025
Kellner (Theodore D)
37.20K
1.3%
+17.51K
+88.91%
Oct 24, 2025
Sabby Management, LLC
28.86K
1.01%
+28.86K
--
Sep 30, 2025
The Vanguard Group, Inc.
17.50K
0.61%
+17.50K
--
Sep 30, 2025
Deutsch (Todd A)
17.16K
0.6%
--
--
Dec 19, 2024
Geode Capital Management, L.L.C.
16.19K
0.57%
+16.19K
--
Sep 30, 2025
Mitchell (William M)
5.22K
0.18%
-4.00
-0.08%
Oct 24, 2025
Rodino (Peter W III)
4.01K
0.14%
-7.00
-0.17%
Oct 24, 2025
Appelrouth (Stewart L.)
3.89K
0.14%
+670.00
+20.82%
Dec 31, 2024
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 03, 2025
Merger
100→1
Date
Ex-dividend Date
Type
Ratio
Mar 03, 2025
Merger
100→1
